Multiple Myeloma Research Consortium (MMRC)
pipeline offers promising treatments for patients
Clinical trials promise innovative therapeutics to help
extend and save the lives of those living with multiple myeloma
1
A Record Breaking Year
In 2014, the MMRC, along with our
The second half of the year was equally
Another trial that opened at the end
industry and academic partners, opened
successful, with the opening of an
of 2014 is studying a novel, four-drug
a record number of clinical trials —
additional four trials. These included
combination of Velcade® (bortezomib),
a total of 10. These trials spanned the
two Phase II trials evaluating ixazomib
Revlimid, dexamethasone and
multiple myeloma spectrum — testing
in the post-transplant setting. Ixazomib
elotuzumab in newly diagnosed multiple
drugs in relapsed/refractory patients as
is an oral proteasome inhibitor
myeloma patients. Elotuzumab is an
well as recently diagnosed patients and
currently in the final stages of clinical
antibody that is currently in late stage
those in the post-transplant setting.
development, which will provide new
clinical development and works by two
2
insights on easier and more convenient
distinct mechanisms. This antibody
ways to administer drugs of this class.
can bind to a protein (SLAMF7) on the
In the first half of 2014, we opened
six trials to study drugs that align
with our core research priorities:
surface of myeloma cells and signal
•
Ravi Vij, M.D. at Washington
the immune cells to destroy the tumor.
immunotherapies and antibodies,
University is leading a Phase II
and novel agents and mechanisms.
Additionally, elotuzumab can directly
Study of ixazomib, Revlimid, and
Covered in the previous installment
activate the types of immune cells
dexamethasone (IRD) for con-
of Accelerator, these included:
needed to destroy myeloma tumor cells.
solidation therapy post-Autologous
The lead site for this clinical trial is Dana-
Stem Cell Transplantation (ASCT)
Farber Cancer Institute and is being
followed by maintenance with
overseen by Paul Richardson, M.D. and
ixazomib or Revlimid.
Jacob Laubach, M.D., M.P.P.
•
Marizomib (NPI-0052) in combination
with Pomalyst® and low dose
dexamethasone — Novel Agent
•
Imbruvica® (ibrutinib) in combination
•
The second study, a Phase II
Finally, a Phase Ib study of SAR650984
randomized trial of continuation
antibody is being tested in combination
of post-transplant maintenance
with Kyprolis® (carfilzomib) in relapsed/
with Kyprolis® and dexamethasone —
with single-agent Revlimid vs.
refractory patients. The lead MMRC
Novel Mechanism
consolidation/maintenance with
investigator is Tom Martin, M.D. of the
•
SAR650984 (anti-CD38) — Antibody
ixazomib, Revlimid, dexamethasone
University of California, San Francisco.
•
Ixazomib (MLN9708) in combination
in patients with residual myeloma,
The MMRC is also studying this investi-
with Pomalidomide —Novel Agent
is being led by Andrzej Jakubowiak,
gational treatment in combination with
M.D., Ph.D. at the University
Revlimid and dexamethasone and as a
of Chicago.
single agent.
with Kyprolis® — Novel Mechanism
•
Selinexor (KPT-330) in combination
•
CB-5083 — Novel Mechanism
EV E NTS
8
19
T HE MMRF.ORG